Protocol Ledger

NCT03580044 · Phase III · TERMINATED

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

Interventional Phase III clinical trial protocol NCT03580044 sponsored by Pfizer in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-12-25 Enrollment: 15 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03580044
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)15 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03580044
Protocol FieldVerified Registry Value
NCT IdentifierNCT03580044
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment15 participants (ACTUAL)
Registered Start Date2020-12-25
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03580044
Hospital Research SiteLocationSite Profile
Banner University Medical Center - TucsonTucson, AZOpen Hospital Dossier ->
Huashan Hospital, Fudan UniversityShanghai, ChinaOpen Hospital Dossier ->
University General Hospital of LarissaLarissa, GreeceOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI